Table 2.
Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type and treatment regimen
| CR | PR | SD | PD | p value | |
|---|---|---|---|---|---|
| Total (n = 363) | 1 (0.3) | 265 (73.0) | 72 (19.8) | 25 (6.9) | < 0.001 |
| EGFR mutation types | |||||
| E19del (n = 175) | 1 (0.6) | 132 (75.4) | 33 (18.9) | 9 (5.1) | |
| L858R (n = 154) | 0 | 117 (76.0) | 30 (19.5) | 7 (4.5) | |
| Uncommon (n = 34) | 0 | 16 (47.1) | 9 (26.5) | 9 (26.5) | |
| EGFR TKIs | 0.914 | ||||
| Afatinib (n = 102) | 0 | 74 (72.5) | 21 (20.6) | 7 (6.9) | |
| Erlotinib (n = 139) | 1 (0.7) | 100 (71.9) | 29 (20.9) | 9 (6.5) | |
| Gefitinib (n = 122) | 0 | 91 (74.6) | 22 (18.0) | 9 (7.4) | |
Data are shown as n (%) per each group
CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations, EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors